Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.000504%Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis24.12.03.004; 12.02.01.002--
Photopsia17.17.01.006; 06.02.06.0040.000112%
Photosensitivity reaction23.03.09.003--
Platelet transfusion25.06.01.001--Not Available
Pleural effusion22.05.02.0020.002071%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonitis22.01.01.0060.003806%
Pneumothorax22.05.02.003--
Pollakiuria20.02.02.007--
Polydipsia05.03.03.002; 14.05.02.001--Not Available
Polyneuropathy17.09.03.0120.001903%Not Available
Polyuria20.02.03.002--Not Available
Portal hypertension24.08.06.001; 09.01.06.0060.000112%
Pre-eclampsia24.08.07.002; 20.01.08.002; 18.02.03.0020.000112%Not Available
Premature labour18.07.01.0020.000112%Not Available
Premature rupture of membranes18.07.01.0030.000168%Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000862%
Proctalgia07.03.02.0010.000112%
Productive cough22.02.03.005--
Prothrombin time normal13.01.02.039--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pseudomembranous colitis07.19.01.003; 11.02.02.002--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.000336%
Pulmonary haemorrhage24.07.01.016; 22.12.01.0090.000224%
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene